No annual revenue total was found in AN2 Therapeutics, Inc.'s SEC filings.
AN2 Therapeutics, Inc. (ANTX) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income (TTM)
$-36.27M
+2.8% vs year-ago TTM
Operating cash flow (TTM)
$-30.68M
+13.6% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-1.04
+16.4% vs year-ago TTM
Dividend per share
None
Shares outstanding
35.94M
+19.4% vs prior year
Net cash
$99.22M
FY 2022
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ANTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Menlo Park, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1880438
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
|---|---|---|---|---|
| Operating income | -$38.1M | -$56.8M | -$69.6M | -$42.3M |
| Net income | -$35.2M | -$51.3M | -$64.7M | -$41.0M |
| Diluted EPS | -$1.16 | -$1.72 | -$2.74 | -$2.79 |
| Operating cash flow | -$29.8M | -$49.3M | -$53.3M | -$33.5M |
| Total assets | $62.0M | $92.1M | $138.7M | $102.6M |
| Total liabilities | $8.9M | $10.2M | $14.0M | $7.2M |
| Stockholders' equity | $53.1M | $81.8M | $124.7M | $95.4M |
| Cash and investments | $60.0M | $88.6M | $134.5M | $99.3M |
| Total debt | — | — | — | $53,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 9, 2026 | Jun 3, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 4, 2026 | Jun 4, 2026 |
| 10-Q | Quarterly report | May 11, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 11, 2026 | May 11, 2026 |
All 384 AN2 Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.